As India began rolling out its Covid-19 vaccine last week, lakhs of citizens were inoculated. While there were only a few score adverse reactions after the first day, now at least 447 people have reported adverse effects of the vaccination, a report stated on Sunday.
According to provisional data released, the majority of the people facing side effects complained of headache, nausea and a headache.
While there has been one fatality, authorities have yet not confirmed if it is due to the vaccination. A 46-year-old ward boy in a district hospital in Uttar Pradesh’s Moradabad died 24 hours after taking the vaccination.
The man identified as Mahipal Singh began feeling uneasy on Saturday immediately after receiving the jab. After attending his duties at night, he complained of uneasiness in his chest, breathlessness and cough the next morning, after which he was rushed to the hospital. The doctors at the district hospital pronounced him dead on arrival. Mahipal’s family members said he was a little unwell before he took the vaccine but his condition deteriorated after taking the jab.
India has granted emergency use authorization to two covid-19 vaccines, Pune-based Serum Institute of India’s Covishield and Hyderabad-based Bharat Biotech International Ltd’s Covaxin, for the vaccination drive.
All beneficiaries of the vaccination so far have received Bharat Biotech’s Covid vaccine, Covaxin. In the state of Maharashtra, the government has decided to temporarily suspend the first dose of the vaccine, due to technical issues with the CoWin App, and it plans to restart vaccinations after January 18th.
In a few weeks, India plans to ship off doses of its Covid-19 vaccine to its neighbours, as part of its vaccine diplomacy. The first destinations would be the immediate neighbouring countries like Nepal, Bangladesh, Bhutan, Myanmar, Maldives, Mauritius, Sri Lanka to help kick start their own vaccination drives. The first shipments would be a goodwill gesture, while subsequently, the countries concerned would get on a payment basis from either Serum Institute, or Bharat Biotech.